Mazdutide functions as a dual agonist at both GLP‑1 and glucagon receptors, combining the appetite‑suppressing and glucose‑lowering effects of GLP‑1 with the energy‑expenditure benefits of glucagon activation.[2][6] This dual mechanism distinguishes it from single‑target GLP‑1 agonists and has shown robust weight loss efficacy in clinical trials. Phase 2 studies demonstrated 6.7–11.3% body weight reduction at 3–6 mg weekly doses over 24 weeks.[2] A 48‑week phase 3 trial reported sustained weight loss of 11–14% with 4–6 mg weekly maintenance.[3] In type 2 diabetes populations, mazdutide achieved meaningful HbA1c reductions (~1.7%) alongside ~7% weight loss.[4] The extended half‑life enables convenient once‑weekly dosing with steady pharmacologic exposure.
